“Patients with DPYD variations are 25.6X more likely to experience treatment related death on standard‐dose fluoropyrimidine chemotherapy (5‐fluorouracil or capecitabine).” – Kristine Ashcraft, President and Founder of YouScript
Read more about Kristine’s thoughts on the recent FDA safety announcment regarding DPYD testing in “Screening for DPD: Q&A with Kristine Ashcraft” by Pharmaceutical Executive by clicking here.
